Our results suggest that GATA2 directs enzalutamide-induced transcription by recruiting AR, MED1/MED14, and Pol II to regulatory elements of enzalutamide-responsive genes, revealing a novel role of GATA2 in directing antagonist-mediated transcription in prostate cancer. The gene discussed is AR; the disease is prostate cancer.